Targeting oncogenic vulnerabilities in triple negative breast cancer: biological bases and ongoing clinical studies

Alberto Ocana _ and Atanasio Pandiella

PDF  |  HTML  |  How to cite

Oncotarget. 2017; 8:22218-22234. https://doi.org/10.18632/oncotarget.14731

Metrics: PDF 2379 views  |   HTML 6254 views  |   ?  


Alberto Ocana1 and Atanasio Pandiella2

1 Unidad de Investigación Traslacional, Hospital Universitario de Albacete, Universidad de Castilla La Mancha, Albacete, Spain

2 Instituto de Biología Molecular y Celular del Cáncer and CIBERONC. CSIC-Universidad de Salamanca, Salamanca, Spain

Correspondence to:

Alberto Ocana, email:

Keywords: triple negative breast cancer, breast cancer, kinases, novel therapies

Received: December 12, 2016 Accepted: January 11, 2017 Published: January 18, 2017


Triple negative breast cancer (TNBC) is still an incurable disease despite the great scientific effort performed during the last years. The huge heterogeneity of this disease has motivated the evaluation of a great number of therapies against different molecular alterations. In this article, we review the biological bases of this entity and how the known molecular evidence supports the current preclinical and clinical development of new therapies. Special attention will be given to ongoing clinical studies and potential options for future drug combinations.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 14731